ČESKÁ UROLOGIE / CZECH UROLOGY – 3 / 2019

193 PŘEHLEDOVÝ ČLÁNEK Ces Urol 2019; 23(3): 186–193 4. Sagalovich D, Say R, Kaouk J, Mehrazin R. The role of extended venous thromboembolism prophylaxis following urologic pelvic surgery. Urol Oncol. 2018; 36(3): 83–87. 5. Tikkinen KAO, Craigie S, Agarwal A, et al. Procedure‑specific risks of thrombosis and bleeding in uro‑ logical cancer surgery: systematic review and meta‑analysis. Eur Urol. 2018; 73: 242–251. 6. Tikkinen KAO, Craigie S, Agarwal A, et al. Procedure‑specific risks of thrombosis and bleeding in uro‑ logical non‑cancer surgery: systematic review and meta‑analysis. Eur Urol. 2018; 73: 236–241. 7. Violette PD, Cartwright R, Briel M, Tikkinen KAO, Guyatt GH. Guideline of guidelines: thrombopro‑ phylaxis for urological surgery. BJU Int. 2016; 118: 351–358. 8. Tikkinen KAO, Cartwright R, GouldMK, et al. EAU guidelines on thromboprophylaxis in urological surge‑ ry. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1. 9. Gumulec J, Zänger M, Procházka V, Urbanec R, Klement P. Prevence žilního tromboembolizmu v chi‑ rurgii, laparoskopické chirurgii, urologii. Vnitř Lék. 2009; 55(3): 196–203. 10. Jordan BJ, Matulewicz RS, Trihn B, Kundu S. Venous thromboembolism after nephrectomy: incidence, timing and associated risk factors froma national multi‑institutional database. World J Urol. 2017; 35: 1713–1719. 11. Klaassen Z, Arora K, Goldberg H, et al. Extended venous thromboembolism prophylaxis after radical cystectomy: a call for adherence to current guidelines. J Urol. 2017; 197(2): 302–307. 12. McAlpine K, Breau RH, Mallick R, et al. Current guidelines do not sufficiently discriminate venous thromboembolism risk in urology. Urol Oncol. 2017; 35: 457. e1-457.e8. 13. Chen EC, Papa N, Lawrentschuk N, Bolton D, Sengupta S. Incidence and risk factors of venous thrombo‑ embolism after pelvic uro‑oncologic surgery – a single center experience. BJU Int. 2016; 117 (Suppl 4): 50–53. 14. Heinc P, Táborský M, Kováčik F, Lazárová M, Přeček J. Perioperační riziko v éře nových antikoagulancií. Urol. Praxi 2013; 14(2): 77–80. 15. Musil D, Študent V. Prevence a léčba tromboembolické nemoci v urologii. Urol. Praxi. 2003: 1: 14–18. 16. Ellis G, Camm JA, Datta SN. Novel anticoagulants and antiplatelet agents; a guide for the urologist. BJU Int. 2015; 116: 687–696. 17. Browne E, Haroon U, Davis NF, Forde JC. Perioperative management of new oral anticoagulants in urological surgery. Curr Urol. 2017; 11: 169–174. 18. Mottet N, Bergh RCN, Briers E, et al. EAU guidelines on prostate cancer. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1. 19. Sahin C, Can U, EryildirimB, Sarica K. Transient cessation of antiplatelet medication before percutaneous stone surgery: does it have any safety concern on bleeding related problems? Urolithiasis. 2017; 45: 371–378. 20. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in co‑ ronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio‑Thoracic Surgery (EACTS). Eur Heart J. 2018; 39(3): 213–260. 21. Bashar A, Kautzner J. Perioperační péče o pacienty užívající antikoagulancia. Interv Akut Kardiol. 2017; 16(1): 18–22. 22. Devereaux, PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014; 370: 1494–1503. 23. Gumulec J. Hematologie na JIP/ARO, management antikoagulační prevence v krizových situacích. Transfuze a hematologie dnes. 2018: 124–132. ISSN 1213–5763. 24. Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14: 623–627.